Nanochon
Nanochon develops 3D-printed synthetic orthopedic implants for articular cartilage repair, focusing on minimally invasive treatments for patients ineligible for joint replacement. The company utilizes advanced biomaterials and additive manufacturing to deliver implants that provide immediate mechanical support while promoting biological integration and cartilage regeneration. Nanochon supports its technology with preclinical animal studies, in vitro validation, and regulatory-driven clinical trials across North America.
Industries
N/A
Patents
Three-dimensionally printed tissue engineering scaffolds for tissue regeneration
2025-11-04 • US-12458499-B2
View DetailsThree-dimensionally printed tissue engineering scaffolds for tissue regeneration
2020-04-21 • US-10624750-B2
View Details
Three-dimensionally printed tissue engineering scaffolds for tissue regeneration
2025-11-04 • US-12458499-B2
View DetailsThree-dimensionally printed tissue engineering scaffolds for tissue regeneration
2020-04-21 • US-10624750-B2
View DetailsProducts
Synthetic composite implant created using additive manufacturing, intended to restore full-thickness cartilage lesions, provide mechanical joint support, and promote host tissue integration.
Synthetic composite implant created using additive manufacturing, intended to restore full-thickness cartilage lesions, provide mechanical joint support, and promote host tissue integration.
Services
Production and supply of synthetic, 3D-printed orthopedic implants designed for articular cartilage repair, including process scale-up for clinical and commercial use.
Production and supply of synthetic, 3D-printed orthopedic implants designed for articular cartilage repair, including process scale-up for clinical and commercial use.
Expertise Areas
- Cartilage repair
- Orthopedic medical devices
- Biomaterials engineering
- Additive manufacturing for medicine
Key Technologies
- 3D printing
- Synthetic composite biomaterials
- Porous scaffold design
- MRI-based pre-operative planning
Key People
Investors
MedTech Innovator
Announced on 2024-05-29.
UVA Licensing & Ventures Group
$4,000,000 funded.
Announced on 2024-05-06.
cultivate(MD)
Announced on 2023-11-27.
Venture Round - NANOCHON
$3,991,279 funded.
Announced on 2023-08-28.
UVA Licensing & Ventures Group
$2,000,000 funded.
Announced on 2021-09-16.
Creative Destruction Lab (CDL)
Announced on 2021-01-01.
MedTech Innovator
Announced on 2024-05-29.
UVA Licensing & Ventures Group
$4,000,000 funded.
Announced on 2024-05-06.
cultivate(MD)
Announced on 2023-11-27.
Venture Round - NANOCHON
$3,991,279 funded.
Announced on 2023-08-28.
UVA Licensing & Ventures Group
$2,000,000 funded.
Announced on 2021-09-16.
Creative Destruction Lab (CDL)
Announced on 2021-01-01.
News & Updates
Closed an oversubscribed $4.1M Seed Prime II round, bringing total capital raised to $11.3M.
Received a manufacturing assistance grant to support scale-up at an ISO 13485 facility.
Obtained regulatory and ethics approvals in 2025 to launch a 10-patient first-in-human clinical study.
Profile highlighting the company's technology and founder's background in engineering and regenerative medicine.
Interview with CTO Nathan Castro discussing cartilage repair technology and additive manufacturing.
Industry article on company technology and progress toward clinical trials.
Closed an oversubscribed $4.1M Seed Prime II round, bringing total capital raised to $11.3M.
Received a manufacturing assistance grant to support scale-up at an ISO 13485 facility.
Obtained regulatory and ethics approvals in 2025 to launch a 10-patient first-in-human clinical study.
Profile highlighting the company's technology and founder's background in engineering and regenerative medicine.
Interview with CTO Nathan Castro discussing cartilage repair technology and additive manufacturing.
Industry article on company technology and progress toward clinical trials.